en.Wedoany.com Reported - NVision Imaging Technologies GmbH, a quantum technology company headquartered in Ulm, Germany, announced on May 13, 2026, the completion of a $55 million Series B funding round, bringing its total cumulative funding to $120 million. This round was led by Abbott as the sole strategic investor, with the European Investment Bank providing a $17 million venture loan, and existing investors including Playground Global, Matterwave/b2ventures, and Entrée Capital continuing their participation. The company also announced its formal expansion from the field of quantum-enhanced sensing into quantum computing, and unveiled a new photonic integrated quantum circuit architecture called PIQC.
Sella Brosh, CEO and co-founder of NVision, explained the logic behind this strategic expansion: quantum computers will generate a vast number of drug candidate hypotheses for currently difficult-to-treat diseases, and the POLARIS platform will undertake the role of rapid in vivo validation. The synergy between the two closes the feedback loop between design and reality. Peter Barrett, General Partner at Playground Global, noted that NVision is fundamentally changing the way cancer is discovered, diagnosed, and treated, and that the same molecular quantum capabilities can now simultaneously drive the design and testing of new therapies.
The core of NVision's newly released PIQC architecture is a class of organic molecular qubits discovered during the development of POLARIS. These qubits operate in a single-photon emission mode, representing a fundamental departure from traditional qubit technology approaches. NVision has integrated these molecular qubits directly onto photonic chips in the form of a thin film, with the overall process being compatible with standard semiconductor manufacturing technologies. The PIQC platform is specifically optimized for complex system simulation and drug candidate identification, providing an engineering path from first principles for large-scale, scalable quantum hardware.
The company's existing quantum sensing product, POLARIS, has already made clear progress in commercial deployment. The platform utilizes quantum technology to enhance the MRI signal of metabolic imaging agents by more than 10,000 times, enabling real-time imaging on standard hospital MRI systems. This allows physicians to assess treatment response based on disease biology within hours, without waiting for the morphological changes that traditional imaging requires weeks or months to observe. POLARIS can operate in a standard hospital environment, without relying on specialized quantum technology operators or cryogenic infrastructure beyond the conditions of ordinary medical facilities. As of this funding announcement, POLARIS systems have been deployed at leading global institutions such as the Memorial Sloan Kettering Cancer Center, the Department of Radiology at the University of Cambridge, and the Technical University of Munich, with approximately 20 research and clinical centers expected to be operational across the United States, Europe, and Asia by the end of 2026.
NVision was founded in 2015 by quantum physicists from Ulm University. The company previously received $19.5 million in funding from the German government and completed a $30 million Series A funding round led by Playground Global in 2023. With the completion of this $55 million Series B round, total cumulative funding reaches $120 million. The funds will be used to continue advancing the global deployment expansion of POLARIS and the engineering development of the PIQC quantum computing platform.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
